Financial News from The Finance Reveal, updated August 24, 2026. This article is general information, not investment or medical advice.

One of the most dramatic single-day stock moves in recent memory happened this week, and it offers a vivid lesson about a particular corner of the market. Shares of the drugmaker Moderna soared roughly 175 percent in a single session after it and its partner Merck announced that their personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial for melanoma, the first time such an individualized therapy has passed that bar. It was a genuine scientific milestone. It is also a case study in why one category of investing is so uniquely volatile.

The science is exciting on its own terms, but for investors the striking detail is the sheer size of the move, and the contrast between the two companies. Merck, an enormous, diversified pharmaceutical giant, rose a solid but modest 12 percent on the same news. Moderna, a far smaller company whose fortunes hinge on fewer products, nearly tripled. That gap is the whole lesson in miniature.

Why Biotech Stocks Move Like This

Biotech and early-stage drug companies live and die by binary events. A clinical trial either succeeds or it fails, and the result often arrives on a single pre-announced day. When success hits, as it did here, and it exceeds expectations or comes earlier than analysts predicted, the stock can double or more in hours. When a trial fails, the same stock can lose half its value or more just as fast. There is very little middle ground.

This makes smaller biotech firms among the most speculative investments in the public markets. Their value rests heavily on outcomes that are genuinely uncertain until the data reads out, which is why a company can be worth billions more by lunchtime than it was at breakfast. It is the mirror image of the risk our guide on what happens if a stock you own goes bankrupt describes: the same forces that produce a 175 percent gain can, on a different day and a different trial, produce a devastating loss.

Why It Matters for You

The natural temptation after seeing a stock triple is to wish you had owned it, or to go hunting for the next one. That instinct deserves real caution. Buying a biotech stock hoping to catch a trial win is closer to placing a bet than making an investment, because the outcome is largely out of your hands and impossible to predict reliably. For every Moderna that soars, others quietly collapse when their data disappoints, and you rarely read about those.

The sensible way for most people to get exposure to an exciting field like this is not to gamble on a single company but to own many of them at once through a diversified fund, so that one trial failure cannot sink your savings while you still share in the sector’s overall progress. That approach sits at the heart of our guides to risk and diversification and to choosing funds and ETFs. If you do buy individual biotech shares, treat the money as you would any speculative bet: keep it small, and never risk what you cannot afford to lose. A scientific breakthrough can be thrilling and still be a dangerous stock to chase, and knowing the difference, as our guide on buying your first stock stresses, is what separates investing from speculating.

This article is general information, not investment or medical advice. For more market and economic coverage, visit our Financial News section.